Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × efgartigimod alfa × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 2 Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

pembrolizumab 550 Specimen Handling 517 Magnetic Resonance Spectroscopy 448 Carboplatin 361 Cyclophosphamide 337 Biopsy 311 Cisplatin 301 Paclitaxel 269 Nivolumab 258 Gemcitabine 234 Radiotherapy 227 Bevacizumab 199 Dexamethasone 192 fludarabine 183 venetoclax 181 Oxaliplatin 163 Docetaxel 158 Fluorouracil 156 atezolizumab 154 durvalumab 153 Rituximab 150 Pemetrexed 147 Capecitabine 143 Doxorubicin 138 Radiation 133 Lenalidomide 128 Prednisone 126 Standard of Care 123 Radiosurgery 121 Drug Therapy 119

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07217587 2026-03-13

EPIC

Janssen Research & Development, LLC

Phase 3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡